DTIL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 21:34):

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States...

Stats
Dzisiejszy wolumen	12 310.00
Średni wolumen	130 072
Kapitalizacja rynkowa	90.47M
EPS	$0 ( 2024-05-14 )
Następna data zysków	( $-0.770 ) 2024-08-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-08	Amoroso Michael	Buy	8 334	Common Stock
2024-05-08	Kelly John Alexander	Buy	8 334	Common Stock
2024-05-08	Smith J. Jefferson	Buy	833	Common Stock
2024-05-08	Scimeca Dario	Buy	833	Common Stock
2024-05-04	Pire Shari Lisa	Buy	4 202	Common Stock

INSIDER POWER
14.40
Last 100 transactions
Buy: 2 573 781 \| Sell: 1 742 339

Precision BioSciences Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Precision BioSciences Inc Finanse

Annual	2023
Przychody:	$48.73M
Zysk brutto:	$40.47M (83.06 %)
EPS:	$-18.16

FY	2023
Przychody:	$48.73M
Zysk brutto:	$40.47M (83.06 %)
EPS:	$-18.16

FY	2022
Przychody:	$25.10M
Zysk brutto:	$16.09M (64.12 %)
EPS:	$-41.95

FY	2021
Przychody:	$115.53M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Precision BioSciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Precision BioSciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.